Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative rhCollagen-based products, particularly the Collink.3D bioink, which has shown superior performance in structured tissue formation compared to animal-derived alternatives, thereby enhancing its competitive edge in the bioprinting market. The operational U.S. logistics center is expected to drive incremental sales of both BioInk and rhCollagen as demand grows among research institutions and tissue-engineering clients. Additionally, the strategic partnership with Allergan and advancements in regulatory approvals for its dermal filler program position the company well for increased revenue and growth in both regenerative and aesthetic medicine sectors.

Bears say

CollPlant Biotechnologies Ltd faces a challenging financial environment, as evidenced by its recent $2.0 million capital raise, which has resulted in a negative market reaction and raised concerns about investor confidence. The company's pricing actions, particularly at $1.25 per share, indicate persistent pressure on equity and suggest limited opportunities for effective capital formation. Furthermore, revised forecasts for key product segments like Dermal Fillers and BioInk, along with the removal of Breast Implants from projections, highlight a more conservative outlook that may adversely impact future revenue growth.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.